GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (FRA:8STN) » Definitions » Cyclically Adjusted PB Ratio

Sorrento Therapeutics (FRA:8STN) Cyclically Adjusted PB Ratio : (As of May. 26, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Sorrento Therapeutics Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sorrento Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Sorrento Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics Cyclically Adjusted PB Ratio Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.54 2.12 4.15 2.63 0.48

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.08 0.84 0.48 0.20 0.19

Competitive Comparison of Sorrento Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Sorrento Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sorrento Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's Cyclically Adjusted PB Ratio falls into.



Sorrento Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Sorrento Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Sorrento Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book=Book Value per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.404/128.7287*128.7287
=-0.404

Current CPI (Jun. 2023) = 128.7287.

Sorrento Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201309 1.402 98.790 1.827
201312 2.118 98.326 2.773
201403 1.855 99.695 2.395
201406 2.013 100.560 2.577
201409 1.931 100.428 2.475
201412 2.437 99.070 3.167
201503 2.548 99.621 3.292
201506 2.234 100.684 2.856
201509 3.449 100.392 4.423
201512 3.528 99.792 4.551
201603 2.218 100.470 2.842
201606 1.934 101.688 2.448
201609 1.233 101.861 1.558
201612 1.491 101.863 1.884
201703 1.062 102.862 1.329
201706 1.075 103.349 1.339
201709 1.400 104.136 1.731
201712 2.034 104.011 2.517
201803 2.092 105.290 2.558
201806 1.873 106.317 2.268
201809 1.598 106.507 1.931
201812 1.506 105.998 1.829
201903 0.955 107.251 1.146
201906 0.603 108.070 0.718
201909 0.318 108.329 0.378
201912 0.422 108.420 0.501
202003 0.447 108.902 0.528
202006 0.526 108.767 0.623
202009 0.666 109.815 0.781
202012 0.493 109.897 0.577
202103 0.681 111.754 0.784
202106 0.519 114.631 0.583
202109 0.368 115.734 0.409
202112 0.222 117.630 0.243
202203 0.548 121.301 0.582
202206 0.286 125.017 0.294
202209 0.284 125.227 0.292
202212 -0.038 125.222 -0.039
202303 -0.250 127.348 -0.253
202306 -0.404 128.729 -0.404

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sorrento Therapeutics  (FRA:8STN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Sorrento Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Sorrento Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sorrento Therapeutics (FRA:8STN) Business Description

Traded in Other Exchanges
Address
4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

Sorrento Therapeutics (FRA:8STN) Headlines

No Headlines